Background: Percutaneous balloon pulmonary valvuloplasty (BPV) is the first-line treatment for neonatal critical pulmonary stenosis (PS). However, most evidence comes from registries or mixed cohorts that combine neonates with older infants, or critical PS with pulmonary atresia. Single-centre neonatal series are small, and the factors that lead to reintervention are still poorly defined. Objectives: To describe the immediate outcomes of the first BPV in neonates, to estimate the incidence and timing of reintervention and death within 1 year, and to identify clinical, angiographic and haemodynamic factors associated with reintervention. Methods: This was a retrospective, single-centre cohort study of all neonates who underwent a first BPV within the first 31 days of life for isolated critical or severe PS between November 1998 and June 2025 at a tertiary referral centre. Cumulative incidence of reintervention (catheter-based or surgical) was estimated with death as a competing risk. Associated factors were explored with cause-specific Cox models. Results: Of 314 neonates, 183 (58.3%) had critical PS. Median age at BPV was 5 days [IQR 2–11], and the median balloon-to-annulus ratio was 1.28 [1.18–1.36]. BPV was successful in 95.5% of procedures, and the median residual gradient was 10 mmHg [5–16]. Complications occurred in 14.4%, mostly transient, with no perforation or tamponade. Five of 234 neonates with follow-up (2.1%) died in the neonatal period, none after a failed procedure. The cumulative incidence of reintervention was 6.7% at 1 month, 11.8% at 3 months and 17.8% at 1 year. Surgical reinterventions clustered in the first month, while catheter reinterventions accrued mainly between 1 and 3 months. In multivariable analysis, critical PS (HR 3.80, 95% CI 1.07–13.50), the residual pulmonary valve gradient (HR 1.40 per 10 mmHg, 1.08–1.83) and lower birth weight (HR 0.91 per 100 g, 0.85–0.98) were independently associated with reintervention. The balloon-to-annulus ratio was not. One-third of neonates (61/186) were discharged with SpO₂ <90%. They had no excess of reintervention (18.4% vs 13.1%, P = .46), and saturation was near normal at 1 year. Conclusions: In neonates with isolated critical or severe PS, BPV is highly effective and safe. About one in six requires reintervention within 1 year, mostly within 3 months. Critical PS at presentation and the residual valve gradient at the end of the procedure are the main factors associated with this risk, and the latter can guide follow-up. Discharge with persistent desaturation appeared well tolerated.
Background: Percutaneous balloon pulmonary valvuloplasty (BPV) is the first-line treatment for neonatal critical pulmonary stenosis (PS). However, most evidence comes from registries or mixed cohorts that combine neonates with older infants, or critical PS with pulmonary atresia. Single-centre neonatal series are small, and the factors that lead to reintervention are still poorly defined. Objectives: To describe the immediate outcomes of the first BPV in neonates, to estimate the incidence and timing of reintervention and death within 1 year, and to identify clinical, angiographic and haemodynamic factors associated with reintervention. Methods: This was a retrospective, single-centre cohort study of all neonates who underwent a first BPV within the first 31 days of life for isolated critical or severe PS between November 1998 and June 2025 at a tertiary referral centre. Cumulative incidence of reintervention (catheter-based or surgical) was estimated with death as a competing risk. Associated factors were explored with cause-specific Cox models. Results: Of 314 neonates, 183 (58.3%) had critical PS. Median age at BPV was 5 days [IQR 2–11], and the median balloon-to-annulus ratio was 1.28 [1.18–1.36]. BPV was successful in 95.5% of procedures, and the median residual gradient was 10 mmHg [5–16]. Complications occurred in 14.4%, mostly transient, with no perforation or tamponade. Five of 234 neonates with follow-up (2.1%) died in the neonatal period, none after a failed procedure. The cumulative incidence of reintervention was 6.7% at 1 month, 11.8% at 3 months and 17.8% at 1 year. Surgical reinterventions clustered in the first month, while catheter reinterventions accrued mainly between 1 and 3 months. In multivariable analysis, critical PS (HR 3.80, 95% CI 1.07–13.50), the residual pulmonary valve gradient (HR 1.40 per 10 mmHg, 1.08–1.83) and lower birth weight (HR 0.91 per 100 g, 0.85–0.98) were independently associated with reintervention. The balloon-to-annulus ratio was not. One-third of neonates (61/186) were discharged with SpO₂ <90%. They had no excess of reintervention (18.4% vs 13.1%, P = .46), and saturation was near normal at 1 year. Conclusions: In neonates with isolated critical or severe PS, BPV is highly effective and safe. About one in six requires reintervention within 1 year, mostly within 3 months. Critical PS at presentation and the residual valve gradient at the end of the procedure are the main factors associated with this risk, and the latter can guide follow-up. Discharge with persistent desaturation appeared well tolerated.
Short- and Mid-Term Outcomes of Balloon Pulmonary Valvuloplasty in Neonates with Isolated Pulmonary Stenosis: A Single-Centre Retrospective Study
YE, LUISA
2024/2025
Abstract
Background: Percutaneous balloon pulmonary valvuloplasty (BPV) is the first-line treatment for neonatal critical pulmonary stenosis (PS). However, most evidence comes from registries or mixed cohorts that combine neonates with older infants, or critical PS with pulmonary atresia. Single-centre neonatal series are small, and the factors that lead to reintervention are still poorly defined. Objectives: To describe the immediate outcomes of the first BPV in neonates, to estimate the incidence and timing of reintervention and death within 1 year, and to identify clinical, angiographic and haemodynamic factors associated with reintervention. Methods: This was a retrospective, single-centre cohort study of all neonates who underwent a first BPV within the first 31 days of life for isolated critical or severe PS between November 1998 and June 2025 at a tertiary referral centre. Cumulative incidence of reintervention (catheter-based or surgical) was estimated with death as a competing risk. Associated factors were explored with cause-specific Cox models. Results: Of 314 neonates, 183 (58.3%) had critical PS. Median age at BPV was 5 days [IQR 2–11], and the median balloon-to-annulus ratio was 1.28 [1.18–1.36]. BPV was successful in 95.5% of procedures, and the median residual gradient was 10 mmHg [5–16]. Complications occurred in 14.4%, mostly transient, with no perforation or tamponade. Five of 234 neonates with follow-up (2.1%) died in the neonatal period, none after a failed procedure. The cumulative incidence of reintervention was 6.7% at 1 month, 11.8% at 3 months and 17.8% at 1 year. Surgical reinterventions clustered in the first month, while catheter reinterventions accrued mainly between 1 and 3 months. In multivariable analysis, critical PS (HR 3.80, 95% CI 1.07–13.50), the residual pulmonary valve gradient (HR 1.40 per 10 mmHg, 1.08–1.83) and lower birth weight (HR 0.91 per 100 g, 0.85–0.98) were independently associated with reintervention. The balloon-to-annulus ratio was not. One-third of neonates (61/186) were discharged with SpO₂ <90%. They had no excess of reintervention (18.4% vs 13.1%, P = .46), and saturation was near normal at 1 year. Conclusions: In neonates with isolated critical or severe PS, BPV is highly effective and safe. About one in six requires reintervention within 1 year, mostly within 3 months. Critical PS at presentation and the residual valve gradient at the end of the procedure are the main factors associated with this risk, and the latter can guide follow-up. Discharge with persistent desaturation appeared well tolerated.| File | Dimensione | Formato | |
|---|---|---|---|
|
YE_LUISA.pdf
Accesso riservato
Dimensione
2.4 MB
Formato
Adobe PDF
|
2.4 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/120644